Could drug holidays improve thyroid cancer treatment?
NCT ID NCT01813136
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study compares two ways of taking the drug pazopanib for people with advanced differentiated thyroid cancer that no longer responds to radioactive iodine. One group takes pazopanib continuously, while the other takes planned breaks and restarts the drug only if the cancer progresses. The goal is to see if taking breaks can reduce side effects without making the cancer worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pazopanib
What this could lead to
If successful, this could show that intermittent dosing of pazopanib is as effective as continuous treatment, potentially reducing side effects and improving quality of life for patients.
What could go wrong
This is a phase 2 trial with a moderate number of participants, so results may not confirm superiority or non-inferiority. The intermittent schedule might lead to faster disease progression in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Thyroid Cancer Imaging Study for Radiation Safet NCT03986437
- Postoperative Pain After Neck Dissection – NCT06803732
- Sunitinib for Advanced Thyroid Cancer – NCT00510640
- Robotic Thyroidectomy Assessment Score Study (NCT06730321)
- Is Radio-Iodine Needed for Low-Risk Thyroid Canc NCT01398085
- Predicting Difficulty in Thyroid Surgery | NCT06671184
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Lille Hôpital Claude Huriez
Lille, 59037, France
-
CHU Angers
Angers, 49933, France
-
CHU Bordeaux
Bordeaux, 33075, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Leon Berard
Lyon, 69373, France
-
Hôpital Saint-Louis APHP
Paris, 75010, France
-
Hôpital de la Pitié Salpêtrière APHP
Paris, 75651, France
-
Hôpital de la Timone APHM
Marseille, 13385, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Régaud
Toulouse, 31052, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Jean Godinot
Reims, 51726, France